indication

Schizophrenia Patients

Competitive landscape projected to PMS＋Exercise’s launch window

as of 2026-07-01
Competitive set
3
3 approved · 0 pipeline

Projection timeline

actual past → guided future · protection walls overlaid
25 events
2020
2024
2028
2032
2036
2040
today
PMS＋Exercise launch window
guided / estimated ↑
actual ↓
focal / guidedapprovallabel expansiontrial readoutcongressnclustered events (click to expand)guided (dashed = directional)competitor patent cliff

Competitive set

resolved drugs with trials in this indication
drugCompleted
Risperidone
US-approved 1993 · RISPERDAL
Phase 23 trials
OwnerJanssen, L.P. - Investigator Initiated Studies Program
Protection2042
drugCompleted
Lurasidone
US-approved 2010 · Latuda
Phase 11 trial
OwnerSumitomo Pharmaceuticals America
Protection2031
drugCompleted
Paliperidone
US-approved 2006 · Erzofri extended-release
Phase 11 trial
OwnerJohnson & Johnson
Protection2041

Market size

prevalence as a range, not a number